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Abstract
Resistance to Hsp90 inhibition has become an important concern as several clinical trials are currently
in progress for the treatment of cancer. A summary of known mechanisms of resistance to Hsp90
inhibitors is provided, including the recent solution of the Humicola fuscoatra Hsp90 structure, the
organism responsible for the biosynthesis of radicicol. Through careful analyses of Hsp90 structures,
a plausible mechanism for resistance to Hsp90 inhibitors has been obtained by single mutations about
the N-terminal ATP-binding site.
The 90-kDa heat shock proteins (Hsp90) represent a highly conserved class of ATP-dependent
molecular chaperones responsible for the maturation of newly formed polypeptides and the
stability and/or rematuration of denatured polypeptides (1). Although Hsp90 is essential for
normal cell development and proliferation, research has also shown its clientele to include a
myriad of oncogenic proteins. Furthermore, Hsp90-dependent substrates are directly
associated with all six hallmarks of cancer, allowing Hsp90 inhibition to simultaneously disrupt
all oncogenic traits (2).
Known inhibitors act by binding to the N-terminal ATP-binding site, and the potential for
evolving drug resistance via mutation of this domain has been dismissed in both scientific
discussions as well as the literature. The dominant opinion has been that mutations to the ATP-
binding pocket would render Hsp90 unable to bind/hydrolyze ATP and would therefore
compromise its chaperone function. Consequently, resistance to Hsp90 inhibition was believed
limited to drug efflux or metabolic mechanisms of drug inactivation. In contrast to this opinion,
Prodromou et al. (DOI 10.1021/cb9000316) (3) have performed site-directed mutagenesis to
demonstrate that mutation within the Hsp90 N-terminal ATP-binding pocket results in selective
resistance to radicicol (RDC, Figure 1), while maintaining susceptibility to inhibition by
geldanamycin (GDA) and sustaining ATP-hydrolysis activity.
The ability of Hsp90 inhibitors to affect multiple oncogenic signaling pathways has propelled
their potential use for the treatment of various cancers. However, resistance to Hsp90 inhibitors
has been established and liabilities should be considered when developing new therapeutics.
The first example of resistance to Hsp90 inhibitors was discovered prior to identification of
the chaperone as the biological target of the ansamycin, GDA. Research by Benchekroun et
al. (4) noted the ability of cancer cells to acquire resistance to the ansamycin class of natural
products, which was believed to be multifactorial. Subsequent disclosure of Hsp90 as the target
for GDA and recent confirmation of Hsp90 as a viable anticancer target have inspired further
research aimed at elucidating the mechanisms of resistance to Hsp90 inhibitors.
One of the first reports of acquired resistance to Hsp90 inhibitors was noted in hormone-
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in drug efflux and metabolic alterations were cited as the basis for resistance. Accordingly,
Benchekroun and colleagues used photoaffinity-labeling experiments to show that GDA
interacts with the P-170 glycoprotein drug efflux pump (P-gp) and that resistant cells
expressing this efflux pump exhibited decreased intracellular GDA concentrations (Figure 2,
panel a). Additional work has confirmed that GDA is both a substrate and an inhibitor of P-
gp. Not surprisingly, studies have demonstrated that P-gp inhibition resensitizes cells to GDA,
and recent studies by McCollum et al. (6) have reiterated the role of drug efflux pumps for
exhibiting resistance to Hsp90 inhibitiors. In addition, they have also demonstrated induction
of the stress response as an additional factor in the development of resistance (Figure 2, panel
b). For example, when GDA-resistant A549 cells were transfected with Hsp27 and/or Hsp70
siRNA, sensistivity to GDA increased 10-fold, whereas pretreatment with the P-gp inhibitor
verapamil did not resensitize these cells.
Another hypothesis put forth by Benchekroun’s report was that resistance developed from
alteration of the cellular reduction potential (Figure 2, panel c). Subsequent studies identified
NAD(P)H/quinone oxidoreductase 1 (NQ01) as the enzyme responsible for reducing the
quinone ring of GDA to the higher affinity (~40-fold), hydroquinone. Studies by Gaspar et
al. (7) indicated an inverse correlation between NQ01 expression and the IC50 of 17-AAG,
suggesting the mechanism of resistance is a direct consequence of reduction of NQ01 activity.
Although some cell lines maintain lower NQ01 activity, results obtained from Gasper and
colleagues provided the first example of acquired resistance via this mechanism.
Recent elucidation of Hsp90 cochaperones has led to studies aimed at determining the function
of these assistants, as a number of cochaperones are intimately involved with Hsp90 function
(8). For instance, Cox and Miller (9) monitored downstream signaling effects produced by the
aryl hydrocarbon receptor (AhR), an Hsp90-dependent transcription factor, to probe the
relationship between p23/Sba1 and Hsp90 inhibitors (Figure 2, panel d). Their work not only
indicated p23/Sba1 as an N-terminal interactor, but also elucidated its role as a putative
mechanism of resistance to Hsp90 inhibition. Cox and Miller showed that overexpression of
p23/Sba1 diminished the inhibitory activity of N-terminal inhibitors, namely radicicol and
herbimycin A. In separate studies, Forafonov et al. (10) demonstrated that in the absence of
p23/Sba1 yeast and mammalian cells were more susceptible to Hsp90 inhibition. The
competitive role of p23/Sba1 results from their function to bind and stabilize the Hsp90 ATP-
bound form, thus blocking hydrolysis and preventing inhibitor binding. Evidence has shown
that mutants of p23/Sba1 are viable (11), suggesting that p23/Sba1 may fortuitously represent
the first evolutionary mechanism to protect cells from Hsp90 inhibition. Now, with the work
of Prodromou and collegues, there is evidence that further evolutionary pressures may result
in Hsp90 mutants that are capable of hydrolyzing ATP and carrying out normal cellular
functions without the potential of inhibition.
Fungal secondary metabolites have played an important role in medicinal chemistry, especially
in the development of both antimicrobial and antitumor chemotherapies (12). RDC is isolated
from Humicola fuscoatra (13) and has been shown to be a potent inhibitor of Hsp90 in vitro.
Not surprisingly, Hsp90 in H. fuscoatra exhibits much lower affinity for RDC than yeast or
mammalian homologues because this organism must protect itself from its own biosynthetic
products. Isolation and sequencing of the Hsp90 gene from H. fuscoatra revealed two minor
differences in the ATP-binding pocket when compared with that of yeast Hsp90. Therefore,
the authors sought to incorporate these two mutations into yeast Hsp90, which is normally
susceptible to RDC inhibition. Using site-directed mutagenesis, the authors were able to show
that mutation of leucine to isoleucine resulted in selective resistance to RDC by yeast Hsp90.
When the yeast L34I mutant Hsp90 was constructed, resistance to radicicol was observed,
clearly indicating that a single point mutation is sufficient to cause resistance in other
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organisms. Surprisingly, sensitivity to GDA was unaffected and ATP hydrolysis proceeded at
an unaffected rate.
To investigate the diminished RDC inhibitory activity that did not reduce GDA or ATP affinity,
Prodromou et al. solved the co-crystal structures of the three ligands bound to mutant Hsp90.
Comparative analyses of the structures revealed that the L34I mutation altered the hydration
state within the binding pocket by allowing the incorporation of three additional water
molecules, resulting in an unfavorable environment for the chlorine substituent of RDC. The
change in hydration state, however, did not affect ATP binding due to the absence of
hydrophobic groups on the adenine ring. In the case of GDA, the molecule is too large and
does not allow for the accommodation of these water molecules, causing GDA’s affinity to be
unaffected as these water molecules are simply displaced upon binding of the natural product.
In a conclusive study, Prodromou and co-workers demonstrated that minor perturbation of the
Hsp90 ATP-binding pocket can significantly alter the affinity for specific inhibitory ligands
(Figure 2, panel e).
The studies by Prodromou and colleagues indicate that Hsp90 can retain its chaperone function
despite mutations to the ATP-binding pocket. Although these studies provide evolutionary
evidence for a mechanism of resistance to Hsp90 inhibition by RDC, research will demonstrate
whether pressures can produce such mutations in mammalian cells. In addition, this work begs
the question as to how Streptomyces hygroscopicus, the bacteria responsible for GDA
biosynthesis, is protected from Hsp90 inhibition, as GDA analogues are further advanced in
clinical trials than any other Hsp90 inhibitor. Therefore, these studies reemphasize the
importance of understanding the interaction of ligands with Hsp90 and reaffirm the need for
new chemical scaffolds that inhibit the Hsp90 protein folding machinery.
References
1. Pearl LH, Prodromou C, Workman P. The Hsp90 molecular chaperone: an open and shut case for
treatment. Biochem J 2008;410:439–453. [PubMed: 18290764]
2. Wanping X, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a
multifaceted effect on diverse cell signaling pathways of cancer. Clin Cancer Res 2007;13:1625–1629.
[PubMed: 17363512]
3. Prodromou C, Nuttall J, Millson S, Roe S, Pearl L, Workman P, Tiow-Suan S, Tan D, Piper P. The
structural basis of the radicicol resistance displayed by a fungal Hsp90. ACS Chem Biol 2009;4:289–
297. [PubMed: 19236053]
4. Benchekroun MN, Schneider E, Safa AR, Townsend AJ, Sinha BK. Mechanisms of resistance to
ansamycin antibiotics in human breast cancer cells lines. Mol Pharmacol 1994;46:677–684. [PubMed:
7969046]
5. Madden TA, Pumford S, Barrow D, Dutkowski CM, McClelland R, Nicholson RI. Development of
acquired resistance to 17(allylamino)-17-demethoxygeldanamycin (17-AAG) in hormone refractory
breast cancers in vitro. Proc Am Assoc Cancer Res 2005;46 Abstract LB-267.
6. McCollum AK, TenEyck CJ, Stensgard B, Morlan B, Ballman KV, Jenkins RB, Toft DO, Erlichman
C. P-glycoprotein-mediated resistance to Hsp90-directed therapy is eclipsed by the heat shock
response. Cancer Res 2008;68:7419–7427. [PubMed: 18794130]
7. Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, Eccles S, Pearson A, Workman P.
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in
glioblastoma cells. Cancer Res 2009;69:1966–1975. [PubMed: 19244114]
8. Picard, D. www.picard.ch/downloads/Hsp90interactors.pdf
9. Cox MB, Miller CA III. Pharmacological and genetic analysis of 90-kDa heat shock protein
isoproteinaryl hydrocarbon receptor complexes. Mol Pharmacol 2003;64:1549–1556. [PubMed:
14645686]
Duerfeldt and Blagg Page 3













10. Forafonov F, Toogun OA, Grad I, Suslova E, Freeman BC, Picard D. p23/Sba1p protects against
Hsp90 inhibitors independently of its intrinsic chaperone activity. Mol Cell Biol 2008;28:3446–3456.
[PubMed: 18362168]
11. Fang Y, Fliss AE, Rao J, Caplan AJ. Sba1 encodes a yeast Hsp90 cochaperone that is homologous
to vertebrate p23 proteins. Mol Cell Biol 1998;18:3727–3734. [PubMed: 9632755]
12. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prod
2007;70:461–477. [PubMed: 17309302]
13. Wicklow DT, Joshi BK, Gamble WR, Gloer JB, Dowd PF. Antifungal metabolites (monorden,
monocillin IV, and cerebrosides) from Humicola fuscoatra traaen NRRL 22980, a mycoparasite of
Aspergillus flavus sclerotia. Appl Environ Microbiol 1998;64:4482–4484. [PubMed: 9797310]
Duerfeldt and Blagg Page 4















Duerfeldt and Blagg Page 5














Mechanisms of resistance to Hsp90 inhibitors: a) drug efflux via P-gp pumps; b) induction of
heat shock response; c) decreased NQ01 enzymatic activity, which is responsible for reduction
of the GDA quinone to the higher affinity hydroquinone; d) competitive binding of p23/Sba1
to the Hsp90 N-terminus; and e) mutation to the N-terminal binding pocket (L34I), which alters
the hydration state.
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